Andrew Perlman
Fondatore presso Jetti Resources
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Michael Outwin | M | - |
Jetti Resources LLC
Jetti Resources LLC Information Technology ServicesTechnology Services Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin.
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 10 anni |
Mike Outwin | M | - |
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada.
Jetti Resources LLC
Jetti Resources LLC Information Technology ServicesTechnology Services Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin. | - |
Oron Afek | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | - |
Rick O'Connor | M | - |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | - |
Cameron Andrews | M | - |
Sirona Medical, Inc.
Sirona Medical, Inc. Packaged SoftwareTechnology Services Sirona Medical, Inc. develops medical image software and provides health care services . The company was founded in 2018 and is headquartered in San Francisco, CA. | 6 anni |
Grant Zimmerman | M | - |
AMP Americas LLC
AMP Americas LLC Other TransportationTransportation AMP Americas LLC operates as an integrated transport company. The company was founded by Nathan Laurellis and Steve Josephs in 2011 and is headquartered in Chicago, IL. | 9 anni |
Susan Petty | F | - |
AltaRock Energy, Inc.
AltaRock Energy, Inc. Miscellaneous Commercial ServicesCommercial Services AltaRock Energy, Inc. develops and commercializes geothermal technology. It develops and commercializes geothermal technology to produce clean and renewable power. The company was founded by Robert Banack, Aaron H. Mandell and Susan Petty in 2007 and is headquartered in Seattle, WA. | 17 anni |
Julie Sunderland | F | 51 |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | - |
Yael Adam | F | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | 10 anni |
Aaron Mandell | M | - |
AltaRock Energy, Inc.
AltaRock Energy, Inc. Miscellaneous Commercial ServicesCommercial Services AltaRock Energy, Inc. develops and commercializes geothermal technology. It develops and commercializes geothermal technology to produce clean and renewable power. The company was founded by Robert Banack, Aaron H. Mandell and Susan Petty in 2007 and is headquartered in Seattle, WA. | 17 anni |
Will Weisman | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | 9 anni |
Ashley Sommerschield | F | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 7 anni |
Charles Goodyear | M | - |
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada.
Jetti Resources LLC
Jetti Resources LLC Information Technology ServicesTechnology Services Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin. | - |
Trevor L. Reid | M | 64 |
Jetti Resources LLC
Jetti Resources LLC Information Technology ServicesTechnology Services Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin.
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada. | - |
Mike McCormick | M | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 7 anni |
Ken Pickering Ewen | M | 76 |
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada.
Jetti Resources LLC
Jetti Resources LLC Information Technology ServicesTechnology Services Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin. | - |
Cory Sago | M | - |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | - |
Asaf David | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | 9 anni |
James Dahlman | M | - |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | - |
Chris Mora | M | - |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | 11 anni |
Seth Winterroth | M | 35 |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | - |
Gautam Krishnamurthi | M | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 3 anni |
D. J. Patil | M | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 1 anni |
Randall Mays | M | 58 |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Ramez Naam | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Richard Lungen | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | 6 anni |
Marc Hodosh | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Eric O Brien | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Erik Engelson | M | - |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | - |
Carl Tremblay | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | 2 anni |
John Pearce | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | 2 anni |
Francisco Gimenez | M | - |
Sirona Medical, Inc.
Sirona Medical, Inc. Packaged SoftwareTechnology Services Sirona Medical, Inc. develops medical image software and provides health care services . The company was founded in 2018 and is headquartered in San Francisco, CA. | - |
Khaled bin Talal | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Scott Hairston | M | - |
Jetti Resources LLC
Jetti Resources LLC Information Technology ServicesTechnology Services Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin. | - |
Ismail Kola | M | 67 |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | 2 anni |
Raymond Lane | M | 77 |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 9 anni |
Erik Engelson | M | 64 |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | 2 anni |
Kent S. Marquardt | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | 7 anni |
Dan Klinglesmith | M | - |
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada. | - |
Konstantinos Alataris | M | - |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | - |
Michael Masterson | M | - |
Invicta Medical, Inc.
Invicta Medical, Inc. Medical SpecialtiesHealth Technology Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA. | 3 anni |
Barney Pell | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Ashok Krishnamurthi | M | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 7 anni |
Zem Spire Joaquin | F | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Jonathan Weiner | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Hugo Schumann | M | - |
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada. | 5 anni |
Jeff Rosenthal | M | 39 |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
David Agger | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Mary Jepsen | M | 59 |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Stephen Renfro | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | 6 anni |
Mei Mei Hu | F | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Daniel Malchuk | M | 58 |
Jetti Resources
Jetti Resources Information Technology ServicesTechnology Services Jetti Resources develops novel hydrometallurgical technology. It uses to extract metals, copper and low grade primary sulfide from mineral ores that the mining industry. The company was founded by Mike Outwin and is headquartered in Vancouver, Canada. | - |
Albert Osterloh | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Sam Bramfeld | M | - |
AMP Americas LLC
AMP Americas LLC Other TransportationTransportation AMP Americas LLC operates as an integrated transport company. The company was founded by Nathan Laurellis and Steve Josephs in 2011 and is headquartered in Chicago, IL. | 9 anni |
Tal Morgenstern | M | - |
Vim, Inc.
Vim, Inc. Packaged SoftwareTechnology Services Vim, Inc. engages in operation of a booking platform that provides healthcare services. It connects customers to healthcare providers through an app called VIM. The company was founded by Asaf David and Yael Peled Adam in 2015 and is headquartered in Los Angeles, CA. | - |
William Brody | M | 80 |
Sirona Medical, Inc.
Sirona Medical, Inc. Packaged SoftwareTechnology Services Sirona Medical, Inc. develops medical image software and provides health care services . The company was founded in 2018 and is headquartered in San Francisco, CA. | 1 anni |
Andrew Hessel | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | - |
Khaled Mouasher | M | - |
KittyHawk Ventures LLC
KittyHawk Ventures LLC Investment ManagersFinance KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California. | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Thomas Hughes | M | 64 | 10 anni | |
Neal C. Isaacson | M | 62 |
Cignal Global Communications, Inc.
Cignal Global Communications, Inc. Specialty TelecommunicationsCommunications Part of Liberty Global Ltd., Cignal Global Communications, Inc. is an internet service provider. The company is based in Cambridge, MA. The company was founded by Neal C. Isaacson, Andrew Perlman. Cignal Global Communications was acquired by United Pan-Europe Communications NV on April 01, 2000. | 6 anni |
Christoph Westphal | M | 56 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 6 anni |
Paul Schimmel | M | 83 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
Lou Tartaglia | M | 60 | 7 anni | |
Bruce Booth | M | 49 | 12 anni | |
David Sinclair | M | 55 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Matthias B. Jaffé | M | 50 | 4 anni | |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Peter Barrett | M | 71 | - | |
James E. Vath | M | 62 | - | |
Saad Qais | M | - |
AMP Americas LLC
AMP Americas LLC Other TransportationTransportation AMP Americas LLC operates as an integrated transport company. The company was founded by Nathan Laurellis and Steve Josephs in 2011 and is headquartered in Chicago, IL. | - |
Kevin Starr | M | 61 | 9 anni | |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
Maria Rupnick | F | - | - | |
Andrew Nichols | M | 63 | 1 anni | |
Roger Xie | M | 54 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 3 anni |
Jill Milne | M | 56 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
David Sinclair | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 6 anni |
Robert Banack | M | - |
AltaRock Energy, Inc.
AltaRock Energy, Inc. Miscellaneous Commercial ServicesCommercial Services AltaRock Energy, Inc. develops and commercializes geothermal technology. It develops and commercializes geothermal technology to produce clean and renewable power. The company was founded by Robert Banack, Aaron H. Mandell and Susan Petty in 2007 and is headquartered in Seattle, WA. | - |
Daanish Jamal | M | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 3 anni |
Suzanne Ronnholm | F | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Brian Shin | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 2 anni |
Michael van Buskirk | M | - |
Coatue Corp.
Coatue Corp. SemiconductorsElectronic Technology Part of Advanced Micro Devices, Inc., Coatue Corp. is one of the largest dedicated technology funds in the world. Coatue has offices in different locations and is based in Woburn, MA. The company's dedicated team of engineers and data scientists works closely with investment professionals to add value to founders and executive teams in their portfolio. Some of their private investments include airtable, ant financial, anaplan, bytedance, chime, databricks, doordash, instacart, meituan, snap, snowflake, and spotify. The company, founded by Andrew Perlman, Aaron H. Mandell, and Avi Y. Goldberg, manages approximately $17 billion in assets on behalf of individuals, endowments, foundations, and other institutional investors. Coatue was acquired by Advanced Micro Devices, Inc. from ITU Ventures LLC on August 05, 2003. | 1 anni |
Avi Y. Goldberg | M | 47 |
Cignal Global Communications, Inc.
Cignal Global Communications, Inc. Specialty TelecommunicationsCommunications Part of Liberty Global Ltd., Cignal Global Communications, Inc. is an internet service provider. The company is based in Cambridge, MA. The company was founded by Neal C. Isaacson, Andrew Perlman. Cignal Global Communications was acquired by United Pan-Europe Communications NV on April 01, 2000. | 2 anni |
Stephen Kraus | M | 47 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 2 anni |
John Freund | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
Paul Brannelly | M | 51 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
Stephen Hoffman | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
Wilfred Jaeger | M | 67 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 3 anni |
John Clarke | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 anni |
Jared Schwitzke | M | - |
Greatpoint Investment Management LLC
Greatpoint Investment Management LLC Investment ManagersFinance Greatpoint Investment Management, LLC (GreatPoint Ventures) is a venture capital firm founded in 2004 by Andrew Perlman, Avi Y. Goldberg and Aaron H. Mandell. The firm is headquartered in San Francisco, California. | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 88 | 96.70% |
Canada | 7 | 7.69% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Andrew Perlman
- Contatti personali